Crohn's Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
Summary
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan, Canada) and provides an Excel-based forecast model for Crohn's Disease market through 2032.
GlobalData estimates Crohn's Disease (CD) drug sales across the 8MM covered in this report will increase from $9.5 billion to $15.0 billion, at a compound annual growth rate (CAGR) of 4.7%, by the end of the forecast period in 2032. The growth of the market will be driven by the approval and launches of 15 pipeline, generic, and biosimilar therapies.
Major drivers of CD market growth over the forecast period are the -
- The emergence within the market of novel and innovative therapies that provides significant improvement in therapeutic efficacy over current treatments
- Successful legal rulings in favor of pharmaceutical companies over the legality of drug price legislature in the US
- Updated recommendations for the rapid incorporation of newer therapies by healthcare providers
- Legislature by the US government to reduce drug prices resulting in lower sales in the largest global market
- The emergence of several biosimilar and generic drugs entering the US market
- Disruption of the pharmaceutical supply chain and the production of biologics due to geopolitical events
GlobalData estimates that sales of drugs in the CD market was approximately $9.5 billion in 2022 in the 8MM. The global CD market is expected to grow to $15.0 billion in 2032, at a Compound Annual Growth Rate (CAGR) of 4.7%.
Major drivers of CD market growth over the forecast period are the -
- The emergence within the market of novel and innovative therapies that provides significant improvement in therapeutic efficacy over current treatments
- The launch of the MK-7240 companion diagnostic test
- Updated recommendations for the rapid incorporation of newer therapies by healthcare providers
- Overview of CD including epidemiology, disease etiology and management.
- Topline CD drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
- Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, Japan, and Canada over the 10-year forecast period.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global CD therapeutics market. Insightful review of the key industry drivers and barriers.
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global CD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global CD therapeutics market from 2022-2032.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- About GlobalData
- 1 Crohn’s Disease: Executive Summary
- 1.1 Steady growth is expected for the CD market from 2022-32
- 1.2 Novel MOAs will provide market shifts throughout the forecast period
- 1.3 Lack of tools to properly treat patients with CD is a clear unmet need within the market
- 1.4 Pipeline Drugs
- 1.5 What Do Physicians Think?
- 2 Introduction
- 2.1 Catalyst
- 2.2 Related reports
- 2.3 Upcoming reports
- 3 Disease Overview
- 3.1 Etiology and pathophysiology
- 3.1.1 Etiology
- 3.1.2 Pathophysiology
- 3.1.3 CD Classification
- 4 Epidemiology
- 4.1 Disease background
- 4.2 Risk factors and comorbidities
- 4.3 Global and historical trends
- 4.4 8MM forecast methodology
- 4.4.1 Sources
- 4.4.2 Forecast assumptions and methods
- 4.4.3 Forecast assumptions and methods: diagnosed incident cases of CD
- 4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of CD
- 4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of CD by severity, diagnosed prevalent cases of fistulizing CD by severity, and diagnosed prevalent cases of CD in remission by severity
- 4.5 Epidemiological forecast for Crohn’s disease (2022-32)
- 4.5.1 Diagnosed incident cases of CD
- 4.5.2 Age-specific diagnosed incident cases of CD
- 4.5.3 Sex-specific diagnosed incident cases of CD
- 4.5.4 Diagnosed prevalent cases of CD
- 4.5.5 Age-specific diagnosed prevalent cases of CD
- 4.5.6 Sex-specific diagnosed prevalent cases of CD
- 4.5.7 Diagnosed prevalent cases of CD by severity
- 4.5.8 Diagnosed prevalent cases of fistulizing CD by severity
- 4.5.9 Diagnosed prevalent cases of CD in remission by severity
- 4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 COVID-19 impact
- 4.6.3 Limitations of the analysis
- 4.6.4 Strengths of the analysis
- 5 Disease Management
- 5.1 Diagnosis and treatment overview
- 5.2 KOL insights on disease management
- 6 Current Treatment Options
- 6.1 Overview
- 7 Unmet Needs and Opportunity Assessment
- 7.1 Overview
- 7.2 Improved Drug Efficacy, Clinical Response, and Sustained Remission
- 7.3 Biomarkers to Predict Responsiveness to Therapy and Prognosis
- 7.4 Improved Medical Management of Perianal Fistulas
- 7.5 Clinical Data to Determine the Most Efficacious Therapy
- 8 R&D Strategies
- 8.1 Overview
- 8.1.1 Novel MOAs
- 8.1.2 Biomarkers
- 8.2 Clinical Trials Design
- 8.2.1 Patient inclusion criteria
- 8.2.2 Endpoints
- 9 Pipeline Assessment
- 9.1 Overview
- 9.2 Promising drugs in clinical development "
- 1 About GlobalData
- 10.1 Overview
- 10.2 Competitive Assessment "
- 1 About GlobalData
- 11.1 Overview
- 11.2 Deal-Making Trends "
- 1 About GlobalData
- 12.1 Global Markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers - global issues
- 12.2 US
- 12.2.1 Forecast
- 12.2.2 Key events
- 12.2.3 Drivers and barriers
- 12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key events
- 12.3.3 Drivers and barriers
- 12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key Events
- 12.4.3 Drivers and barriers
- 12.5 Canada
- 12.5.1 Forecast
- 12.5.2 Key events
- 12.5.3 Drivers and barriers "
- 1 About GlobalData
- 13.1 Bibliography
- 13.2 Abbreviations
- 13.3 Methodology
- 13.3.1 Forecasting Methodology
- 13.4 Primary Research - KOLs Interviewed for This Report
- 13.4.1 KOLs
- 13.5 Primary Research - Prescriber Survey
- 13.6 About the Authors
- 13.6.1 Analyst
- 13.6.2 Managing Analyst
- 13.6.3 Epidemiologist
- 13.6.4 Reviewers
- 13.6.5 Global Director of Therapy Analysis and Epidemiology
- List of Tables
- Table 1: CD: Key metrics in the 8MM
- Table 2: Crohn’s disease severities
- Table 3: Risk factors and comorbidities for CD
- Table 4: Treatment guidelines for CD
- Table 5: Top 10 deals by value, 2011-2022
- Table 6: CD market - global drivers and barriers, 2022-32
- Table 7: Key events impacting sales for CD in the US, 2022-32
- Table 8: CD market - drivers and barriers in the US, 2022-32
- Table 9: Key events impacting sales for CD in the 5EU, 2022-32
- Table 10: CD market - drivers and barriers in the 5EU, 2022-32
- Table 11: Key events impacting sales for CD in Japan, 2022-32
- Table 13: Key events impacting sales for CD in Canada, 2022-32
- Table 14: CD market - drivers and barriers in Canada, 2022-32
- Table 15: High-prescribing physicians (non-KOLs) surveyed, by country
- List of Figures
- Figure 1: Global sales forecast by country for CD in 2022 and 2032
- Figure 2: Analysis of the company portfolio gap in CD during the forecast period
- Figure 3: Competitive assessment of the late-stage biologics benchmarked against Humira
- Figure 4: Competitive assessment of the late-stage small molecules benchmarked against Rinvoq
- Figure 5: Pathophysiology of Crohn’s Disease
- Figure 6: 8MM, diagnosed incidence of CD, men and women, cases per 100,000 population, all ages, 2022
- Figure 7: 8MM, diagnosed prevalence of CD, men and women, %, all ages, 2022
- Figure 8: 8MM, sources used and not used to forecast the diagnosed incident cases of CD
- Figure 9: 8MM, sources used and not used to forecast the diagnosed prevalent cases of CD
- Figure 10: 8MM, diagnosed incident cases of CD, N, both sexes, all ages, 2022
- Figure 11: 8MM, diagnosed incident cases of CD by age, N, both sexes, 2022
- Figure 12: 8MM, diagnosed incident cases of CD by sex, N, all ages, 2022
- Figure 13: 8MM, diagnosed prevalent cases of CD, N, both sexes, all ages, 2022
- Figure 14: 8MM, diagnosed prevalent cases of CD by age, N, both sexes, 2022
- Figure 15: 8MM, diagnosed prevalent cases of CD by sex, N, all ages, 2022
- Figure 16: 8MM, diagnosed prevalent cases of CD by severity, N, both sexes, ages<18 years, 2022
- Figure 17: 8MM, diagnosed prevalent cases of CD by severity, N, both sexes, ages ≥18 years, 2022
- Figure 18: 8MM, diagnosed prevalent cases of fistulizing CD by severity, N, both sexes, ages<18 years, 2022
- Figure 19: 8MM, diagnosed prevalent cases of fistulizing CD by severity, N, both sexes, ages ≥18 years, 2022
- Figure 20: 8MM, diagnosed prevalent cases of CD in remission by severity, N, both sexes, ages<18 years, 2022
- Figure 21: 8MM, diagnosed prevalent cases of CD in remission by severity, N, both sexes, ages ≥18 years, 2022
- Figure 22: Unmet needs and opportunities in CD
- Figure 23: Overview of the development pipeline in CD
- Figure 24: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for CD in the 8MM during the forecast period
- Figure 25: Competitive assessment of the late-stage biologics benchmarked against Humira
- Figure 26: Competitive assessment of the late-stage small molecules benchmarked against Rinvoq
- Figure 27: Analysis of the company portfolio gap in CD during the forecast period
- Figure 28: Global (8MM) sales forecast by country for CD in 2022 and 2032
- Figure 29: Sales forecast by class for CD in the US in 2022 and 2032
- Figure 30: Sales forecast by class for CD in the 5EU in 2022 and 2032
- Figure 31: Sales forecast by class for CD in Japan in 2022 and 2032
- Figure 32: Sales forecast by class for CD in Canada in 2022 and 2032
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook